Midday Movers & Shakers: Biotech Buzz, Treasury Vision & Green Tech Breakouts

2025-09-10 12:59:40 ET

DENVER, Colo., Sep 10, 2025 ( 247marketnews.com )- Lixte Biotechnology (NASDAQ:LIXT) is attracting investor attention as bullish sentiment builds around its lead compound LB?100, a first-in-class Protein Phosphatase 2A (PP2A) inhibitor dubbed a “cancer power-up” for its ability to enhance chemotherapy and immunotherapy. With fewer than 5 million shares outstanding, LIXT’s low float and high short interest (60% borrow fee, 400% maintenance requirement) make it a prime candidate for a short squeeze, potentially pushing it toward new 52-week highs. Currently in clinical trials for ovarian clear-cell carcinoma with GlaxoSmithKline (NYSE: GSK) , LB?100 is poised for a breakout, potentially spearheading a move to 52-week highs. Stay alert for upcoming oncology conferences or favorable Phase 2 trial data that could fuel extended gains.

Cuprina Holdings (NASDAQ:CUPR) secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology under the UNIDO/GEF framework. This steam-based sterilization process transforms plastic medical waste into high-value resins, a sustainable alternative to incineration. Starting with Singapore and potentially expanding into 10 regional countries, the move positions Cuprina as a leader in rising environmental standards and transformative waste management infrastructure.

With Singapore’s biohazardous waste rising from 4,400 tons in 2016 to 5,700 tons in 2020 (MOH Singapore), and the Asia-Pacific medical waste management market projected to grow at a 10.2% CAGR to $15.8 billion by 2030 (Grand View Research), CUPR is well-positioned to capitalize on tightening environmental standards.

Wearable Devices (NASDAQ:WLDS) : Up 4.1%, driven by growing interest in its neural interface wearables. The global wearable technology market, valued at $61.3 billion in 2024, is projected to reach $186.1 billion by 2030 (CAGR 20.2%, Statista), fueling WLDS’s momentum.

Asset Entities (NASDAQ:ASST) recent digital marketing partnerships keep it on watch. The global digital marketing market is expected to hit $1.5 trillion by 2030 (CAGR 17.6%, Grand View Research).

Travere Therapeutics (NASDAQ:TVTX) is gaining on positive Phase 3 data for rare kidney disease treatments. The rare disease market, valued at $195 billion in 2024, is projected to grow at a 9.2% CAGR through 2030 (EvaluatePharma).

Immuneering (NASDAQ:IMRX) is driven by optimism for its oncology pipeline. The global oncology market, at $223 billion in 2025, is expected to reach $530 billion by 2032 (Grand View Research).

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by Microcap Advisory for providing ongoing LIXT market outreach and other services. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/ . Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information.

The post Midday Movers & Shakers: Biotech Buzz, Treasury Vision & Green Tech Breakouts appeared first on 24/7 MarketNews .

For further details see: